Pharma IQ Members

Amorphous Materials

Amorphous Materials, also known as soft glasses, deform and flow through a collective movement of their particles. These materials (which include chocolate mousse, shaving cream, mayonnaise, metallic glasses, granular materials and mud) are amorphous solids, in other words, they are resistant like solids but, like liquids, lack a crystalline structure. Colloids, emulsions, window glass, dense polymers, and even biological tissues are some examples.

12 results
of 2
Pharma IQ News

Medical Research Council (MRC) scientists have created the world’s first enzymes made from artificial genetic material. Their synthetic enzymes, which are made from molecules that do not occur anywhere in nature, are capable of triggering...

Contributor: Pharma IQ News
Thu, 12/04/2014
Andrea Charles

Implementing effective pathogen safety strategies is essential for preventing contamination and ensuring the safety of your biologics. Raw materials can bring a pathogen or virus into your manufacturing plant and raw material control is of...

Contributor: Andrea Charles
Mon, 09/10/2012
Pharma IQ Surveys

In preparation for the 8th Annual Improving Solubility Summit, taking place in June, Pharma IQ would like to invite you to take part in a short survey. The survey consists of no more than 8 questions and will take less than 3 minutes to complete...

Contributor: Pharma IQ Surveys
Fri, 04/27/2012
Ensuring Stability the Biggest Amorphous Challenge for 88.2% of Developers

The use of amorphous pharmaceutical materials is widely considered an effective way of improving favourable drug properties and the latest findings from Pharma IQ suggest that many developers consider them an essential resource. But as Marc...

Contributor: Pharma IQ
Wed, 07/27/2011
Amber Scorah

Amorphous spray dried dispersions (SDDs) have emerged as a broadly applicable technology for the delivery of poorly soluble drug molecules. Methods for formulating and predicting the physical stability of these formulations are becoming better...

Contributor: Amber Scorah
Wed, 03/09/2011
Helen Winsor

Amorphous pharmaceutical materials are now being recognised as an attractive alternative route for solid state development. Dr. Dave Miller, Senior Principal Scientist at Hoffmann-La Roche, speaks to Helen Winsor from Pharma IQ, about the...

Contributor: Helen Winsor
Sun, 09/05/2010
Pharma IQ

Dr. Dave Miller, Senior Principal Scientist at Hoffmann La Roche, shares his views on how to optimise amorphous form selection, techniques to enhance amorphous drug performance and the best strategies to stabilise amorphous forms. He also offers...

Contributor: Pharma IQ
Sun, 07/11/2010
Be Prepared for Scale Up of Co-crystal Production

Dr. Vaibhav Sihorkar, Head of Pharmaceutical Development at Aurigene Discovery Technologies in India, gave Pharma IQ his insights on existing challenges to co-crystal commercialisation.What is the major challenge in achieving scale up of co-...

Contributor: Vaibhav Sihorkar
Tue, 07/06/2010
12 results
of 2